In low-risk myelodysplastic syndrome, don’t shoot the <i>STAG2</i>

Natasha Szuber; Lambert Busque

doi:10.1182/blood.2025030114

In low-risk myelodysplastic syndrome, don’t shoot the <i>STAG2</i>

N Natasha Szuber (1University of Montreal) L Lambert Busque (Faculty of Medicine, Université de Montréal, Montreal, QC, Canada (J.-C.T., L.B., J.C.G., P.L.L., M.-P.D.).)

Download PDF View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Blood

Volume / Issue Vol. 146, Issue 14

Published October 02, 2025

Pages 1636-1638

DOI 10.1182/blood.2025030114

ISSN 0006-4971

Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (2)

N

Natasha Szuber

1University of Montreal

L

Lambert Busque

Faculty of Medicine, Université de Montréal, Montreal, QC, Canada (J.-C.T., L.B., J.C.G., P.L.L., M.-P.D.).

In low-risk myelodysplastic syndrome, don’t shoot the <i>STAG2</i>

Article Details

Journal Info

Authors (2)

Related Articles from this Journal

NOTCHing the MSC-endothelial interplay in the HSC niche

Procr+ endothelial progenitor cells govern hematopoiesis through fine-tuning mesenchymal stem cell niche signals

Li C, Wu B, Li Y, et al. Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness. <i>Blood</i> . 2022;140(15):1686-1701.

Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis

Granulopoiesis under attack by mutant IDH1